文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

Avdoralimab(抗C5aR1单克隆抗体)对比安慰剂治疗重症COVID-19:FOR COVID Elimination(FORCE)随机对照试验结果

Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]).
PubMed 文献 · Crit Care Med · 2022-10-10
一句话结论在重症COVID-19住院患者中,avdoralimab未能显著改善第14天和第28天临床状态或第28天无呼吸机天数。

FORCE是一项在法国12个临床中心(ICU和综合医院)开展的双盲、安慰剂对照随机试验,纳入需≥5 L/min氧疗维持SpO2>93%(WHO量表≥5)的重症COVID-19患者207例,按1:1随机接受avdoralimab或安慰剂。主要终点为队列1和3第14天和第28天WHO序贯量表临床状态、队列2第28天无呼吸机天数(VFD28)。结果显示avdoralimab未改善队列1第28天WHO评分(组间差异-0.26,95%CI -1.2至0.7;p=0.7)、队列3第28天WHO评分(组间差异-0.28,95%CI -1.8至1.2;p=0.6)及队列2的VFD28(组间差异-6.3,95%CI -13.2至0.7;p=0.96),任何队列的次要终点亦未改善,未识别出获益亚组。

要点

  • 在需≥5 L/min氧疗维持SpO2>93%(WHO量表≥5)的重症COVID-19患者中,avdoralimab未改善第14天和第28天WHO临床量表评分。
  • 队列1第28天WHO评分组间差异-0.26(95%CI -1.2至0.7;p=0.7),队列3组间差异-0.28(95%CI -1.8至1.2;p=0.6),均未达统计学显著。
  • 队列2第28天无呼吸机天数(VFD28)组间差异-6.3(95%CI -13.2至0.7;p=0.96),avdoralimab未改善VFD28。
  • avdoralimab未改善任何队列的次要终点,未识别出获益亚组。
  • 住院期间95%的患者接受了糖皮质激素治疗。

适用人群与场景

  • 需≥5 L/min氧疗维持SpO2>93%(WHO量表≥5)的重症COVID-19住院患者。
  • 队列1:接受常规氧疗或经鼻高流量氧疗(HFO)/无创通气(NIV)的患者。
  • 队列2:接受HFO、NIV或有创机械通气(IMV)的患者。
  • 队列3:接受有创机械通气(IMV)的患者。

研究设计与关键结果

  • 研究类型:双盲、安慰剂对照随机试验(FORCE),在法国12个临床中心(ICU和综合医院)开展,共随机207例患者(队列1 99例、队列2 49例、队列3 59例),按1:1随机接受avdoralimab或安慰剂。
  • 主要终点:队列1和3为第14天和第28天WHO序贯量表临床状态;队列2为第28天无呼吸机天数(VFD28)。
  • 队列1第28天WHO评分组间差异-0.26(95%CI -1.2至0.7;p=0.7);队列3第28天WHO评分组间差异-0.28(95%CI -1.8至1.2;p=0.6)。
  • 队列2第28天VFD28组间差异-6.3(95%CI -13.2至0.7;p=0.96)。
  • avdoralimab未改善任何队列的次要终点,未识别出获益亚组。
  • 住院期间95%的患者接受了糖皮质激素治疗。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Severe COVID-19 is associated with exaggerated complement activation. We assessed the efficacy and safety of avdoralimab (an anti-C5aR1 mAb) in severe COVID-19.

DESIGN: FOR COVID Elimination (FORCE) was a double-blind, placebo-controlled study.

SETTING: Twelve clinical sites in France (ICU and general hospitals).

PATIENTS: Patients receiving greater than or equal to 5 L oxygen/min to maintain Sp o2 greater than 93% (World Health Organization scale ≥ 5). Patients received conventional oxygen therapy or high-flow oxygen (HFO)/noninvasive ventilation (NIV) in cohort 1; HFO, NIV, or invasive mechanical ventilation (IMV) in cohort 2; and IMV in cohort 3.

INTERVENTIONS: Patients were randomly assigned, in a 1:1 ratio, to receive avdoralimab or placebo. The primary outcome was clinical status on the World Health Organization ordinal scale at days 14 and 28 for cohorts 1 and 3, and the number of ventilator-free days at day 28 (VFD28) for cohort 2.

MEASUREMENTS AND MAIN RESULTS: We randomized 207 patients: 99 in cohort 1, 49 in cohort 2, and 59 in cohort 3. During hospitalization, 95% of patients received glucocorticoids. Avdoralimab did not improve World Health Organization clinical scale score on days 14 and 28 (between-group difference on day 28 of -0.26 (95% CI, -1.2 to 0.7; p = 0.7) in cohort 1 and -0.28 (95% CI, -1.8 to 1.2; p = 0.6) in cohort 3). Avdoralimab did not improve VFD28 in cohort 2 (between-group difference of -6.3 (95% CI, -13.2 to 0.7; p = 0.96) or secondary outcomes in any cohort. No subgroup of interest was identified.

CONCLUSIONS: In this randomized trial in hospitalized patients with severe COVID-19 pneumonia, avdoralimab did not significantly improve clinical status at days 14 and 28 (funded by Innate Pharma, ClinicalTrials.gov number, NCT04371367).

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Carvelli J, Meziani F, Dellamonica J, et al. Avdoralimab (Anti-C5aR1 mAb) Versus Placebo in Patients With Severe COVID-19: Results From a Randomized Controlled Trial (FOR COVID Elimination [FORCE]). Crit Care Med. 2022. PMID: 36218354. doi:10.1097/CCM.0000000000005683

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。